Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 0911 • ACR Convergence 2021
Drug Retention of Tumor Necrosis Factors and IL-17 Inhibitors in Axial Spondyloarthritis: A Multi-Center Comparative Analysis
Thibaut Delépine¹, Peggy PHILIPPE², Emeline CAILLIAU³, Eric HOUVENAGEL⁴, Tristan Pascart⁵, Xavier DEPREZ⁶, Rene-Marc FLIPO⁷ and Jean-Guillaume LETAROUILLY², ¹Lille University Hospital, Lille, France, ²Rheumatology Department, University Hospital of Lille, Lille, France, ³Assessment of Health Technologies and Medical Practices Department, University Hospital of Lille, Lille, France, ⁴Rheumatology Department, Lille Catholic Hospitals, Lomme, France, ⁵Groupement Hospitalier de l'Institut Catholique de Lille, Lomme, France, ⁶Rheumatology Department, Hospital Center of Valenciennes, Valenciennes, France, ⁷Rheumatology Department, Lille University Hospital, Lille, France
Background/Purpose: Biological disease-modifying antirheumatic drugs (bDMARDs) should be considered in patients with active axial spondyloarthritis (AxSpA) despite treatment with nonsteroidal anti-inflammatory drugs. The objective of…
Abstract Number: 1093 • ACR Convergence 2021
Cardiovascular and Lipid Biomarker Distributions in Inflammatory Arthritis
Bindee Kuriya¹, Shadi Akhtari², Mohammad Movahedi³, Jacob Udell⁴, Patrick Lawler⁴, Paula Harvey⁵ and Lihi Eder⁴, ¹University of Toronto - Toronto, Toronto, ON, Canada, ²Women's College Hospital, University of Toronto, North York, ON, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Women's College Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Inflammatory arthritis (IA) is associated with cardiovascular disease (CVD). Cardiac biomarkers may assist with CVD risk stratification. We aimed to estimate the prevalence, and…
Abstract Number: 1922 • ACR Convergence 2021
Early and Accurate Diagnosis of Patient with Axial Spondyloarthritis Using Machine Learning: A Predictive Analysis from Electronic Health Records in United Kingdom
Raj Sengupta¹, Shruti Narasimham², Borja Mato³, Matic Meglic³, Chiara Perella³, Paula Pamies⁴ and Paul Emery⁵, ¹The Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Novartis Ireland Ltd, Dublin, Ireland, Dublin, Ireland, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Pharmaceuticals UK Ltd, London, UK, London, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: On an average, there is a delay of 6.7 years between symptom onset and diagnosis of axial spondyloarthritis (axSpA)1. Since traditional approaches to improving…
Abstract Number: 0065 • ACR Convergence 2021
Altered Expression of Several miRNAs in Axial Spondyloarthritis Patients with High Disease Activity
Jiri Baloun¹, Kristyna Bubova¹, Aneta Pekacova¹, Monika Gregova², Sarka Forejtova¹, Jana Horinkova¹, Michal Tomcik³, Jindriska Gatterova¹, Jiri Vencovsky¹, Karel Pavelka³ and Ladislav Senolt³, ¹Institute of Rheumatology, Prague, Czech Republic, ²Rheumatology Institute Prague, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Recent studies have shown that microRNAs (miRNAs) play a role in various disorders, including immune mediated inflammatory diseases. Therefore, we studied relationship between miRNA…
Abstract Number: 0369 • ACR Convergence 2021
High Frequency of Complications in Axial Spondyloarthropathy Pregnancies: Emerging Data from the Ankylosing Spondylitis Registry of Ireland
Sinead Maguire¹, Phil Gallagher² and Finbar (Barry) O'Shea¹, ¹St James's Hospital, Dublin, Ireland, ²St Vincent's Hospital, Dublin, Ireland
Background/Purpose: National registries are excellent sources of data to allow analysis of inflammatory arthritis such as axial spondyloarthropathy (axSpA). Our understanding of axSpA has evolved…
Abstract Number: 0820 • ACR Convergence 2021
The PROPER Study: Results of the First 48-week Interim Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Ulf Müller-Ladner¹, Karl Gaffney², Deepak Jadon³, Ulrich Freudensprung⁴ and Janet Addison⁵, ¹JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany, ²Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom, ³Cambridge University Hospitals NHSFT, Cambridge, United Kingdom, ⁴Biogen International GmbH, Baar, Switzerland, ⁵Biogen Idec, Maidenhead, United Kingdom
Background/Purpose: SB5, an adalimumab (ADL) biosimilar, received EU marketing authorisation in August 2017, based on the totality of evidence from pre-clinical and clinical Phase I…
Abstract Number: 0912 • ACR Convergence 2021
Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients with Early versus Late Disease Through Week 52 of GO-ALIVE Study
Atul Deodhar¹, Shelly Kafka², Elizabeth Hsia³, Kim Hung Lo⁴, Kim Lilianne⁴, Stephen Xu³ and John Reveille⁵, ¹Oregon Health & Science University, Portland, OR, ²Department of Immunology, Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Department of Biostatics, Janssen Research & Development, LLC, Spring House, Spring House, PA, ⁵Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: The GO-ALIVE study assessed efficacy and safety of intravenous golimumab (IV GLM) in patients with ankylosing spondylitis (AS).1,2 In this post hoc analysis, we…
Abstract Number: 1219 • ACR Convergence 2021
Machine Learning Based Prediction Model for Responses of bDMARDs in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Seulkee Lee, Seonyoung Kang, Yeonghee Eun, Hyungjin Kim, Jaejoon Lee, Eun-Mi Koh and Hoon-Suk Cha, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Background/Purpose: Few studies on rheumatoid arthritis (RA) have generated machine learning models to predict biologic disease-modifying antirheumatic drugs (bDMARDs) responses; however, these studies included insufficient…
Abstract Number: 1925 • ACR Convergence 2021
Risk of Heart Failure in Patients with Inflammatory Disease: A Population-Based Study
Sahil Koppikar¹, Bindee Kuriya², Jacob Udell³, Bing Yu⁴, Anna Chu⁴, Laura Ferreira-Legere⁵, Douglas Lee³, Jessica Widdifield⁶ and Lihi Eder³, ¹Women's College Hospital, Toronto, ON, Canada, ²University of Toronto - Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴ICES, Toronto, ON, Canada, ⁵ICES, Toronto, Canada, ⁶Sunnybrook Research Institute; ICES; Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Individuals with inflammatory diseases (ID) have an increased risk of cardiovascular disease, frequently compared to that of diabetes mellitus (DM). However, the magnitude of…
Abstract Number: 0066 • ACR Convergence 2021
Characterization of αβTCR of HLA-B*27-Restricted CD8 T-Cell Clones Associated with Spondyloarthropathies
Jose Garrido-Mesa¹, Nicholas Harvey², Aimee Hanson³, Tony Kenna⁴, Chi Wong⁵, Charles Bridgewood⁵, Dennis McGonagle⁵ and Matthew Brown¹, ¹King's College London, London, United Kingdom, ²Molecular Genetics, London, United Kingdom, ³University of Queensland, Brisbane, Australia, ⁴Queensland University of Technology, School of Biomedical Sciences, Brisbane, Australia, ⁵University of Leeds, Leeds, United Kingdom
Background/Purpose: The mechanism by which HLA-B27 induces Ankylosing Spondylitis (AS) and related disease is unknown, but a leading hypothesis is that it presents ‘arthritogenic epitopes’…
Abstract Number: 0372 • ACR Convergence 2021
Impact of Gender and Age on Ankylosing Spondylitis Patient Profiles at Golimumab Initiation and 12-Month Outcomes
Ariel Masetto¹, Proton Rahman², Michelle Teo³, Pauline Boulos⁴, Emmanouil Rampakakis⁵, Meagan Rachich⁶, Allen Lehman⁶, Francois Nantel⁷ and Odalis Asin-Milan⁶, ¹Universite de Sherbrooke, Sherbrooke, QC, Canada, ²Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ³Penticton Regional Hospital, Penticton, BC, Canada, ⁴., Hamilton, ON, Canada, ⁵JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Inc., Toronto, ON, Canada, ⁷., Montréal, QC, Canada
Background/Purpose: Gender and age have been previously identified as independent predictors of response to anti-TNFs. The aim of this analysis was to compare, between genders…
Abstract Number: 0829 • ACR Convergence 2021
Tapering and Withdrawal of Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Inflammatory Arthritis: A Systematic Review and Meta-Analyses of Randomised Trials
Line Uhrenholt¹, Robin Christensen², Wilfred K Dinesen³, Caroline Liboriussen³, Stine Andersen³, Lene Dreyer¹, Annette Schlemmer⁴, Ellen-Margrethe Hauge⁵, Conni Skrubbeltrang⁶ and Salome Kristensen¹, ¹Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ²Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Copenhagen, Denmark, ³Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ⁴Department of Rheumatology, Randers Regional Hospital, Randers, Denmark, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Medical Library, Aalborg University Hospital, Aalborg, Denmark
Background/Purpose: Tapering and withdrawal of biological or targeted synthetic disease-modifying antirheumatic drugs (bDMARDs or tsDMARDs) in patients with inflammatory arthritis (IA) in remission or low…
Abstract Number: 0918 • ACR Convergence 2021
Individual Components Contributing to the Achievement of Assessment in SpondyloArthritis International Society 40 Response in Biologic Naïve Patients with Radiographic Axial Spondyloarthritis: Results from the COAST V Trial
Denis Poddubnyy¹, Suzan Mansour Hussein Attar², Michael J. Nissen³, Erica Fillipi⁴, Hagen Russ⁴, Alper Erdogan⁴, Yves Schymura⁴, Soyi Liu-Leage⁵, Eduardo Collantes-Estevez⁶ and Francesco Ciccia⁷, ¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ²King Abdulaziz University, Jeddah, Saudi Arabia, Jeddah, Saudi Arabia, ³Division of Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁴Eli Lilly and Company Ltd., Indianapolis, IN, ⁵Eli Lilly and Company, Neuilly sur Seine, France, ⁶Department of Rheumatology, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, Cordoba, Spain, ⁷University of Campania “Luigi Vanvitelli", Naples, Italy
Background/Purpose: Ixekizumab (IXE), an IL-17A antagonist, is effective in patients with radiographic axial spondyloarthritis (rad-axSpA). Assessment in SpondyloArthritis International Society (ASAS) 40 response – the…
Abstract Number: 1305 • ACR Convergence 2021
Undiagnosed Depression in Axial Spondyloarthropathy and the Negative Impact on Patient Outcomes: Results of a Screening Study
Sinead Maguire¹, Phil Gallagher² and Finbar (Barry) O'Shea¹, ¹St James's Hospital, Dublin, Ireland, ²St Vincent's Hospital, Dublin, Ireland
Background/Purpose: Previous research in axial spondyloarthropathy(axSpA) has shown this population to have a high prevalence of depression. This co-morbidity has been previously shown to impact…
Abstract Number: 0067 • ACR Convergence 2021
Mendelian Randomisation Analysis of Protein Quantitative Trait Loci with Ankylosing Spondylitis Reveals Causative Involvement of Key Effector Proteins and Pathways
Nicholas Harvey¹, Zhixiu Li², Jose Garrido-Mesa³, Jie Zheng⁴, Paul Wordsworth⁵, John Reveille⁶, Mario Falchi³, Niccolo Rossi³, Alessia Visconti³, David Evans⁷ and Matthew Brown³, ¹Molecular Genetics, London, United Kingdom, ²Queensland University of Technology, Brisbane, Australia, ³King's College London, London, United Kingdom, ⁴Bristol University, Bristol, United Kingdom, ⁵Oxford University, Oxford, United Kingdom, ⁶Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁷University of Queensland, Brisbane, Australia
Background/Purpose: Susceptibility to ankylosing spondylitis (AS) is known to be highly influenced by genetic factors, with heritability assessed in twins of >90%, with >115 genetic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.